Vaccination against M. tuberculosis – what next after BCG?
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2011, Vol 65, Issue 0
Abstract
Tuberculosis (TB) still remains a huge global health problem. An increase in TB has been observed in many parts of the world, especially in poor and densely populated sub-Saharan Africa and Asia. Tuberculosis affects not only the developing countries but also the relatively wealthy regions of Europe, particularly Eastern Europe, where drug-resistant mycobacterial strains are increasingly reported. Control of tuberculosis expansion is very difficult. It requires the long-term use of anti-mycobacterial drugs. Additionally, the HIV epidemic and the phenomenon of multi-drug resistance are assumed to be responsible for the increase in TB cases. Therefore the most reasonable form of anti-TB protection seems to be effective vaccination. At the beginning of the twentieth century the BCG vaccine was introduced into general use as the first and so far the only immune protector against tuberculosis. Now it is known that this vaccine is not powerful enough and induces protection at a relatively low level. Hence ongoing research on the development of a more powerful anti-mycobacterial vaccine is still needed. Many of the new formulations are in phase II or III of clinical trials and the results are promising. The search for new vaccines involves several strategies: modified virulence-attenuated [i]Mycobacterium tuberculosis[/i] strains, recombination of attenuated M. bovis BCG bacilli, immunogenic mycobacterial proteins and DNA encoding selected proteins as well as unrelated microorganisms used as carriers of mycobacterial antigens. The wide range of concepts is extremely important because new vaccines should serve for immunization of the broadest possible population, not only healthy individuals but also those who are immunocompromised.
Authors and Affiliations
Marek Fol, Katarzyna Zawadzka, Magdalena Druszczyńska, Wiesława Rudnicka
Keywords
Related Articles
- EP ID EP66437
- DOI -
- Views 146
- Downloads 0
Perinatal sources of stem cells
Recently, stem cell biology has become an interesting topic. Several varieties of human stem cells have been isolated and identified in vivo and in vitro. Successful application of hematopoietic stem cells in hematology...
Markery zapalenia, aktywacja płytek krwi i zaburzenia krzepnięcia w chorobach zapalnych jelit
Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn’s disease. It is a group of chronic disorders characterized by inflammation of the gastrointestinal track with unknown etiology. Currently applied bi...
Chlamydiosis of urogenitary tract in humans
Chlamydiae are bacteria commonly found in the environment of human life and they cause many diseases. Chlamydial infections are common among men and women, although they are more often diagnosed in women and they are fre...
The role of survivin in the diagnosis and therapy of gynaecological cancers
Survivin is a member of the family of apoptosis inhibitors. It regulates several essential cellular processes, i.e. it inhibits apoptosis and promotes cell proliferation, DNA repair and autophagy. Survivin is responsible...
Znaczenie wybranych przypraw w chorobach sercowo-naczyniowych
Choroby sercowo naczyniowe są główną przyczyną zgonów na świecie. Dane literaturowe podają, że w 2012 r. z ich powodu zmarło około 17,5 mln ludzi. Do grupy chorób układu krążenia zalicza się przede wszystkim choroby: nie...